Trialstirzepatidepakistanobesitytype 2 diabetes

Pakistani cohort to track tirzepatide outcomes in 330 adults

The observational study runs across ten endocrinology centres and follows obesity, prediabetes and type 2 diabetes cohorts for 24 weeks.

By Priya Raman · Science Reporter

Oct 20 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT07809568, sponsored by Universiti Sains Malaysia, will enrol 330 adults starting tirzepatide in routine care, with assessments at baseline, Weeks 12 to 14 and Weeks 24 to 26.
02Primary endpoints are HbA1c change in the diabetes cohort and body weight change in the obesity and prediabetes cohorts, addressing a gap in South Asian data.
03The study is observational and not yet recruiting, with prescribing, dose and duration left to treating physicians, so no control group will anchor the findings.

From the source

Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes
NCT07809568 · N/A · NOT YET RECRUITING · Sponsor: Universiti Sains Malaysia · Conditions: Prediabetes or Overweight, Obesity Type 2 Diabetes Mellitus, Obesity & Overweight.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07809568